

# **Best Evidence Summaries of Topics in Mental Healthcare**

## BEST in MH clinical question-answering service

#### Question

"In individuals with autistic spectrum disorders, what is the most reliable screening tool for attention deficit hyperactivity disorder?"

#### Clarification of question using PICTRO structure

Patients: Individuals with autistic spectrum disorders

Intervention: Screening tool for attention deficit hyperactivity disorder

Comparator: Any other screening tool for attention deficit hyperactivity disorder

Target condition: Attention deficit hyperactivity disorder

Reference standard: Any

Outcome: Sensitivity & specificity

#### Plain language summary

No relevant, high quality research was identified to answer this question.



Email: awp.BESTinMH@nhs.net Phone: 0117 378 4232/4233/4335

#### Clinical and research implications

No relevant, high quality research was identified

#### What does the evidence say?

#### Number of included studies/reviews (number of participants)

N/A

#### **Main findings**

N/A

#### **Authors conclusions**

N/A

#### Reliability of conclusions/Strength of evidence

N/A

#### What do guidelines say?

The NICE guidelines for under 19 year olds with autism (CG128, CG170) make the following recommendations are made for when diagnosing autism:

"Consider whether the child or young person may have any of the following as a coexisting condition, and if suspected carry out appropriate assessments and referrals:

- Mental and behaviour problems and disorders:
  - o ADHD..." (pp.23 CG128)

"Assess factors that may increase the risk of behaviour that challenges in routine assessment and care planning in children and young people with autism, including:

- impairments in communication that may result in difficulty understanding situations or
- in expressing needs and wishes
- coexisting physical disorders, such as pain or gastrointestinal disorders
- coexisting mental health problems such as anxiety or depression and other
- neurodevelopmental conditions such as ADHD..." (CG170 pp.20)

Despite making general recommendations for the diagnosis of ADHD, NICE guidelines do not comment on the diagnosis of ADHD in individuals with autism, or other comorbidities, specifically.

Date question received: 30/06/2016 Date searches conducted: 17/07/2016 Date answer completed: 26/07/2016

#### References

National Institute for Health and Care Excellence (2013) Autism in under 19s: support and management CG170. NICE: LONDON

https://www.nice.org.uk/guidance/cg170/resources/autism-in-under-19s-support-and-management-35109745515205

National Institute for Health and Care Excellence (2011) Autism in under 19s: recognition, referral and diagnosis. CG128.NICE: LONDON

 $\underline{https://www.nice.org.uk/guidance/cg128/resources/autism-in-under-19s-recognition-referral-and-diagnosis-35109456621253}$ 

### **Search details**

Source		Number of hits	Relevant evidence identified
Guidelines	·	<b>'</b>	-I
NICE	Autism	4	2
	Attention		
Systematic Revi	ews		•
MEDLINE	(measure* OR assess* OR screen*).ti,ab	441	0
	autis*.ti,ab		
	exp AUTISTIC DISORDER/		
	48 OR 49		
	"randomized controlled trial".ti,ab		
	"controlled clinical trial".ti,ab		
	randomi\$ed.ti,ab		
	placebo.ti,ab		
	"drug therapy".ti,ab		
	randomly.ti,ab		
	trial.ti,ab		
	groups.ti,ab		
	exp RANDOMIZED CONTROLLED TRIAL/		
	exp CLINICAL TRIAL/ OR exp CONTROLLED CLINICAL TRIAL/		
	51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59 OR 60		
	50 AND 61		
	(ADHD OR (attention adj3 disorder*)).ti,ab		
	exp ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS/ OR exp ATTENTION DEFICIT DISORDER WITH		
	HYPERACTIVITY/		
	63 OR 64		
	62 AND 65		
EMBASE	exp MEASUREMENT/	219	0

	(measure* OR assess* OR screen*).ti,ab exp AUTISM ASSESSMENT/ OR exp AUTISM DIAGNOSTIC INTERVIEW REVISED/ OR exp AUTISM DIAGNOSTIC OBSERVATION SCHEDULE/ 23 OR 24 OR 25 autis*.ti,ab exp AUTISM/ 27 OR 28 26 AND 29 random*.ti,ab factorial*.ti,ab ((crossover* OR cross-over*)).ti,ab placebo*.ti,ab ((doubl* ADJ blind*)).ti,ab ((singl* ADJ blind*)).ti,ab allocat*.ti,ab volunteer*.ti,ab exp "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/ OR exp CONTROLLED CLINICAL TRIAL/ 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 33 AND 44 (ADHD OR (attention adj3 disorder*)).ti,ab exp ATTENTION DEFICIT DISORDER/		
DOVICINEO/CINALI	46 OR 47	266	0
PsycINFO/CINAHL	exp MEASUREMENT/ (measure* OR assess* OR screen*).ti,ab 2 OR 3 exp AUTISM SPECTRUM DISORDERS/ autis*.ti,ab 6 OR 8 4 AND 9 random*.ti,ab	266	0

groups.ti,ab
((double adj3 blind)).ti,ab
((single adj3 blind)).ti,ab
controlled.ti,ab
((clinical adj3 study)).ti,ab
trial.ti,ab
"treatment outcome clinical trial".ti,ab
exp EXPERIMENTAL DESIGN/
8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
7 AND 17
(ADHD OR (attention adj3 disorder\*)).ti,ab
exp ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY/
19 OR 20
18 AND 21

#### Disclaimer

BEST in MH answers to clinical questions are for information purposes only. BEST in MH does not make recommendations. Individual health care providers are responsible for assessing the applicability of BEST in MH answers to their clinical practice. BEST in MH is not responsible or liable for, directly or indirectly, any form of damage resulting from the use/misuse of information contained in or implied by these documents. Links to other sites are provided for information purposes only. BEST in MH cannot accept responsibility for the content of linked sites.

© Best Evidence Summaries of Topics in Mental Health 2015